The answer so far
In plain English, a receptor is one of a cell’s message receivers. Usually it is a protein on the cell surface or inside the cell. When a matching substance binds, the receptor may change shape or activity and start a chain of events; what the cell finally does depends on its other machinery, the amount and timing of exposure, and the tissue. Binding or activation can explain a biological possibility, but it does not by itself show that a medicine helps people.
A receptor is usually a protein that detects a particular signal and helps convert it into a cellular response. Receptors can sit at the cell surface or inside the cell. Binding is the physical interaction; activation is the receptor’s functional change, and the eventual response depends on receptor type, cellular context, downstream circuitry and exposure.12
On this page
- Put it in context
- A signal meets a receptor
- What happens after binding?
- Why the rest of the cell matters
- Receptor families use different wiring
- Where the lock-and-key analogy stops
- Binding, occupancy and response are different measurements
- Why a full response does not prove every receptor was occupied
- Why timing changes interpretation
- Subtype and tissue can change the answer
- What this helps you ask
- Sources
Locate the receptor
Start with a cell. This simplified drawing shows one receptor in its surface membrane. Other receptors are inside cells.
Meet the messenger
A ligand is a molecule that binds a receptor. A messenger made by the body and a medicine can both be ligands.
Separate binding from activation
Binding describes an interaction. Activation describes what happens to the receptor’s response. Those are not identical.
Compare different actions
An agonist activates. A competitive antagonist can prevent an agonist from binding. Partial agonism describes a different maximal response in a defined system.
Notice what is missing
Real signalling involves other molecules, tissue context and feedback. This sequence is a conceptual schematic, not a measured simulation.
Connect it to a clinical question
Knowing the target helps explain the rationale. Trials are needed to investigate benefits and harms in people.
Read all six steps without interaction
1. Locate the receptor
Start with a cell. This simplified drawing shows one receptor in its surface membrane. Other receptors are inside cells.
2. Meet the messenger
A ligand is a molecule that binds a receptor. A messenger made by the body and a medicine can both be ligands.
3. Separate binding from activation
Binding describes an interaction. Activation describes what happens to the receptor’s response. Those are not identical.
4. Compare different actions
An agonist activates. A competitive antagonist can prevent an agonist from binding. Partial agonism describes a different maximal response in a defined system.
5. Notice what is missing
Real signalling involves other molecules, tissue context and feedback. This sequence is a conceptual schematic, not a measured simulation.
6. Connect it to a clinical question
Knowing the target helps explain the rationale. Trials are needed to investigate benefits and harms in people.
Put it in context
Cells have specialised parts and jobs. For example, a hormone in the bloodstream can reach many cells, but only cells with suitable receptors can respond to that signal. A tissue contains cells, and each cell contains many kinds of working molecules. Receptors are part of that machinery—not miniature organs and not holes through which every medicine passes. Surface receptors commonly detect water-soluble signals that cannot freely cross the membrane; intracellular receptors can detect signals that enter the cell, including some lipid-soluble hormones. This page uses a surface receptor as its simplified example and leaves out the structural detail that differs among receptor families.1
A signal meets a receptor
A substance that binds a receptor is called a ligand. It might be a messenger made by the body, an ion, a metabolite or a medicine. Binding is governed by complementary chemical interactions and is usually reversible, so occupancy depends on concentration, affinity, competition and time. A diagram showing two shapes fitting together is a useful introduction, not a literal account of molecular recognition.25
What happens after binding?
An agonist can activate a receptor’s response; an antagonist can block or reduce another substance’s effect. A partial agonist can activate the receptor while producing a smaller maximum response in the system studied. An agonist stabilises a receptor state that can produce a response in the system being studied. An antagonist can reduce an agonist’s effect, often by competing at the receptor, without producing the same response by itself. A partial agonist can produce a smaller maximum response than a full agonist in a specified system and may behave differently when another ligand is present. These terms describe measured pharmacology, not whether a substance is inherently good or bad.2
Why the rest of the cell matters
A receptor interaction can set off a signalling pathway. This can involve ion flow, G proteins, phosphorylation, second messengers or changes in gene expression. Which response follows depends on the receptor’s coupling partners, the proteins expressed by that cell, signal duration and other simultaneous inputs. The same receptor family can participate in different functions across tissues, and receptors can be desensitised or internalised after stimulation. A diagram of one pathway is therefore a selected view, not a complete map of the body.346
Receptor families use different wiring
A ligand-gated ion channel can change ion flow within milliseconds; the nicotinic acetylcholine receptor is a familiar example. A G-protein-coupled receptor can regulate enzymes and second messengers through associated G proteins, as adrenergic receptors do in many tissues. An enzyme-linked receptor such as the insulin receptor can recruit or activate kinases, while an intracellular receptor can alter transcription after binding in the cell, as steroid-hormone receptors can. These are broad families with important exceptions, but the comparison explains why the same word—receptor—can describe very different time courses and experiments.56910
Where the lock-and-key analogy stops
The analogy helps explain selective binding. It is less helpful when it makes a receptor sound like a rigid lock with one possible outcome. Receptors are dynamic proteins; ligand binding can shift ensembles of conformations, recruit different signalling partners and produce pathway-selective effects. One drug can also interact with more than one target. Treat the analogy as a first sketch, then ask what was measured in which preparation.2
Binding, occupancy and response are different measurements
Occupancy means the proportion of available receptors that have a substance bound to them at a particular time. A ligand can bind without producing the response a researcher expects. Binding assays estimate an interaction under defined conditions; occupancy asks how much of a receptor population is engaged; functional assays measure what the cell does. A high-affinity ligand may occupy receptors at a low concentration, but the observed response can still depend on receptor number, coupling efficiency, spare receptors, competing ligands and the assay’s readout. None of these measurements, by itself, establishes a clinical benefit.28611
Why a full response does not prove every receptor was occupied
Some tissues have a receptor reserve (also called spare receptors): downstream amplification means a full measured response can occur while only a fraction of the available receptors is occupied. This is a property of a receptor–cell system, not a fixed label attached to a drug. Changing receptor number, coupling efficiency or the assay can change apparent potency and the size of the reserve. It also helps explain why a partial agonist can look different in two tissues, and why a concentration that produces a large cellular signal does not by itself tell you how many receptors were engaged. Receptor-reserve explanations are models inferred from experiments such as receptor depletion or binding–response comparisons; they should not be treated as a direct measurement unless the study actually measured occupancy.2811
Why timing changes interpretation
Some receptor effects appear quickly and fade when the signal is removed; others require altered gene expression and develop more slowly. Repeated stimulation can reduce responsiveness through phosphorylation, uncoupling, internalisation or changes in receptor production. A single measurement after one exposure can therefore miss adaptation, rebound or delayed toxicity. When reading a study, keep the dose, sampling time, exposure duration and follow-up attached to the claimed response.612
Subtype and tissue can change the answer
Receptor names often hide subtypes and tissue-specific context. For example, adrenergic receptors are grouped into alpha and beta families, and tissues can express different combinations, coupling proteins and downstream enzymes. The same circulating signal can therefore change heart rate in one tissue and alter vascular tone or airway smooth muscle in another. A study that reports activity at one subtype or in one cell line has answered a narrower question than the phrase ‘acts on adrenergic receptors’ suggests. Check the subtype, tissue, concentration and readout before generalising.136
What this helps you ask
When a headline says a medicine “targets a receptor”, ask which receptor, in which setting, with what effect and over what exposure range. Ask whether the result was measured by binding, a cellular assay, a biomarker, a symptom scale or a clinical endpoint—and how that proposed effect was connected to outcomes in people. Knowing the target helps explain the research question. It does not answer the whole clinical question.7
Further reading
Trusted external resources selected to help explain this page. They open in a new tab.
- Receptor ↗A concise scientific definition of receptors and their role in cell signalling.
- What is a cell? ↗A beginner-friendly introduction to the cells that contain receptors and other molecular machinery.
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- Receptor — NCI Dictionary of Cancer TermsNational Cancer Institute · Official scientific reference
- ReceptorsIUPHAR Pharmacology Education Project · Professional educational reference
- Signaling pathway — NCI Dictionary of Cancer TermsNational Cancer Institute · Official scientific reference
- How Do Medicines Work?NIH / NIGMS · Official scientific explainer
- Signaling Molecules and Their ReceptorsNCBI Bookshelf / The Cell: A Molecular Approach · Open biomedical textbook reference
- General Principles of Cell CommunicationNCBI Bookshelf / Molecular Biology of the Cell · Open biomedical textbook reference
- Clinical research trials: The basicsNational Institutes of Health · Official research-literacy guide
- Clinical pharmacodynamicsIUPHAR Pharmacology Education Project · Professional educational reference
- Ion Channels and the Electrical Properties of MembranesNCBI Bookshelf / Molecular Biology of the Cell · Open biomedical textbook reference
- Cholinergic ReceptorsNCBI Bookshelf / Neuroscience · Open biomedical textbook reference
- An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practicePeer-reviewed review / PMC · Pharmacology review reference
- Desensitisation and tachyphylaxisIUPHAR Pharmacology Education Project · Professional educational reference